Our study showed that subjects with severe asthma had higher percent of CD14++CD16+ cells expressing PAR-2 compared to patients with mild/moderate asthma, indicating that PAR-2-expressing CD14++CD16+ monocytes may be involved in the pathogenesis of severe asthma. This evidence concerns the gene CD14 and asthma.